For BRAF/NRAS wild-type PARM where immunotherapy access is limited, adjuvant temozolomide-cisplatin remains a clinically viable consideration, supported by prospective survival data in mucosal melanoma. The gene discussed is NRAS; the disease is mucosal melanoma.